With special thanks to our sponsors for helping support this meeting and to Vertex in Particular who provided an unrestricted educational Grant for the the event. The supporting companies will be exhibiting with trade stands. They have had no input into the agenda or selection of topics or speakers.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
In addition to clinical development programmes in CF, Vertex has more than a dozen ongoing research programmes focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., USA, Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia.
Vertex is consistently recognised as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.
Chiesi Limited is the UK affiliate of the international, privately-owned pharmaceutical company, based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases. The Company was founded in 1935, as a family firm. Chiesi spans the globe, employing more than 4,800 people in 26 affiliates worldwide and sells its products in more than 70 countries.
We embrace innovation which is a constant driver to our continued success. Products wholly, or partially, developed by Chiesi account for three quarters of our sales, with continuous investment in Research and Development.
Chiesi has a portfolio of cystic fibrosis products within Special Care, for which Chiesi has strong ambitions to develop and acquire new medicines. We are committed to providing education and support to cystic fibrosis specialists and patients throughout the UK via a number of organisations.
For more information about Chiesi Limited please visit chiesi.uk.com
CHQUI20180464a March 2018
Mylan ranks among the leading global generic and specialty pharmaceutical companies. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.In the UK, Mylan has one of the largest portfolio of generic and branded generic drugs, offering an extensive range of dosage forms and delivery systems. At Mylan we have one global quality standard in everything we do. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust from physicians, pharmacists, other health care professionals and patients, every day. This is why we say, “Our Mylan is Your Mylan.”
The Medicines Evalution Unit is one of the UK's leading MHRA accredited Clinical Research Organisations with a state-of-the-art, 36 bed facility, based at Wythenshawe Hospital.
We are affiliated with the Manchester Adult Cystic Fibrosis Centre, have the chief investigator capability and have established links with PIC sites at other CF centres.
MEU’s bespoke database and trial management system ICARUS, contains over 100 Cystic Fibrosis patients who actively participate in clinical research. MEU have completed numerous Phase I Cystic Fibrosis studies and dosed dozens of patients.
For more information please visit: www.meu.org.uk
PARI develop solutions for people suffering from respiratory diseases, in the form of high-quality, reliable devices. Voted ‘Brand of the Century’ in 2016 in the field of respiratory therapy by Deutsche Standards, PARI has been a leading manufacturer within the respiratory field for over 100 years.
PARI’s mission is to improve the lives of those affected by respiratory diseases and those who provide care to them. This is reflected in PARI’s comprehensive portfolio of innovative products and services.
PARI products include:
• the eFlow® rapid electronic nebuliser
• the PARI SINUS for treating the upper airways
• MucoClear® hypertonic saline
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.
With special thanks to all our sponsors who have supported the conference. The supporting companies will be exhibiting with trade stands. They have had no input into the agenda or selection of topics or speakers.